These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32766674)

  • 21. Association of Adverse Experiences and Exposure to Violence in Childhood and Adolescence With Inflammatory Burden in Young People.
    Rasmussen LJH; Moffitt TE; Arseneault L; Danese A; Eugen-Olsen J; Fisher HL; Harrington H; Houts R; Matthews T; Sugden K; Williams B; Caspi A
    JAMA Pediatr; 2020 Jan; 174(1):38-47. PubMed ID: 31682707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble Urokinase Receptor and Chronic Kidney Disease.
    Hayek SS; Sever S; Ko YA; Trachtman H; Awad M; Wadhwani S; Altintas MM; Wei C; Hotton AL; French AL; Sperling LS; Lerakis S; Quyyumi AA; Reiser J
    N Engl J Med; 2015 Nov; 373(20):1916-25. PubMed ID: 26539835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.
    Toldi G; Szalay B; Bekő G; Bocskai M; Deák M; Kovács L; Vásárhelyi B; Balog A
    Biomarkers; 2012 Dec; 17(8):758-63. PubMed ID: 23033975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Neurocognitive and Physical Function With Gait Speed in Midlife.
    Rasmussen LJH; Caspi A; Ambler A; Broadbent JM; Cohen HJ; d'Arbeloff T; Elliott M; Hancox RJ; Harrington H; Hogan S; Houts R; Ireland D; Knodt AR; Meredith-Jones K; Morey MC; Morrison L; Poulton R; Ramrakha S; Richmond-Rakerd L; Sison ML; Sneddon K; Thomson WM; Hariri AR; Moffitt TE
    JAMA Netw Open; 2019 Oct; 2(10):e1913123. PubMed ID: 31603488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis.
    Zhang Q; Li L; Chen H; Zhang G; Zhu S; Kong R; Chen H; Wang G; Sun B
    J Clin Lab Anal; 2020 Mar; 34(3):e23097. PubMed ID: 31774228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome.
    Dowsett J; Didriksen M; von Stemann JH; Larsen MH; Thørner LW; Sørensen E; Erikstrup C; Pedersen OB; Hansen MB; Eugen-Olsen J; Banasik K; Ostrowski SR
    Sci Rep; 2022 Jan; 12(1):1672. PubMed ID: 35102231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.
    Godtfredsen NS; Jørgensen DV; Marsaa K; Ulrik CS; Andersen O; Eugen-Olsen J; Rasmussen LJH
    Respir Res; 2018 May; 19(1):97. PubMed ID: 29783959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
    Loosen SH; Tacke F; Püthe N; Binneboesel M; Wiltberger G; Alizai PH; Kather JN; Paffenholz P; Ritz T; Koch A; Bergmann F; Trautwein C; Longerich T; Roderburg C; Neumann UP; Luedde T
    Carcinogenesis; 2019 Aug; 40(8):947-955. PubMed ID: 30805627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity.
    Can U; Buyukinan M; Yerlikaya FH
    Indian J Med Res; 2017 Mar; 145(3):327-333. PubMed ID: 28749394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
    Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
    Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SuPAR, an emerging biomarker in kidney and inflammatory diseases.
    Hamie L; Daoud G; Nemer G; Nammour T; El Chediak A; Uthman IW; Kibbi AG; Eid A; Kurban M
    Postgrad Med J; 2018 Sep; 94(1115):517-524. PubMed ID: 30177549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer.
    Rasmussen LJH; Schultz M; Iversen K; Eugen-Olsen J; Helms M; David K; Kjaer A; Lebech AM; Kronborg G
    Clin Biochem; 2020 Oct; 84():31-37. PubMed ID: 32504704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis.
    Toldi G; Szalay B; Bekő G; Kovács L; Vásárhelyi B; Balog A
    Joint Bone Spine; 2013 Jan; 80(1):96-8. PubMed ID: 22999906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
    Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
    J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
    Rasmussen LJ; Knudsen A; Katzenstein TL; Gerstoft J; Obel N; Jørgensen NR; Kronborg G; Benfield T; Kjaer A; Eugen-Olsen J; Lebech AM
    HIV Med; 2016 May; 17(5):350-7. PubMed ID: 26365671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque.
    Edsfeldt A; Nitulescu M; Grufman H; Grönberg C; Persson A; Nilsson M; Persson M; Björkbacka H; Gonçalves I
    Stroke; 2012 Dec; 43(12):3305-12. PubMed ID: 23150653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission.
    Toldi G; Bekő G; Kádár G; Mácsai E; Kovács L; Vásárhelyi B; Balog A
    Clin Chem Lab Med; 2013 Feb; 51(2):327-32. PubMed ID: 22718576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble urokinase plasminogen activator receptor--a valuable biomarker in systemic lupus erythematosus?
    Enocsson H; Sjöwall C; Wetterö J
    Clin Chim Acta; 2015 Apr; 444():234-41. PubMed ID: 25704300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
    Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A
    Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.